ViroGates A/S
CSE:VIRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sligro Food Group NV
LSE:0MKM
|
NL |
|
Sakai Trading Co Ltd
TSE:9967
|
JP |
|
Eternal Ltd
NSE:ETERNAL
|
IN |
|
Whirlpool Corp
NYSE:WHR
|
US |
|
Bharti Airtel Ltd
NSE:BHARTIARTL
|
IN |
ViroGates A/S
Note Receivable
ViroGates A/S
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
ViroGates A/S
CSE:VIRO
|
Note Receivable
kr181k
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
GN Store Nord A/S
CSE:GN
|
Note Receivable
kr152m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ambu A/S
CSE:AMBU B
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Demant A/S
CSE:DEMANT
|
Note Receivable
kr665m
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
ViroGates A/S
Glance View
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
See Also
What is ViroGates A/S's Note Receivable?
Note Receivable
181k
DKK
Based on the financial report for Sep 30, 2025, ViroGates A/S's Note Receivable amounts to 181k DKK.
What is ViroGates A/S's Note Receivable growth rate?
Note Receivable CAGR 5Y
1%
Over the last year, the Note Receivable growth was 2%. The average annual Note Receivable growth rates for ViroGates A/S have been 1% over the past three years , 1% over the past five years .
